Zobrazeno 1 - 10
of 25
pro vyhledávání: '"S. R. Ytterberg"'
Autor:
M. Dougados, C. Charles-Schoeman, Z. Szekanecz, J. T. Giles, S. R. Ytterberg, D. L. Bhatt, G. G. Koch, I. Vranic, J. Wu, C. Wang, K. Kwok, S. Menon, C. A. Connell, A. Yndestad, J. L. Rivas, M. H. Buch
Publikováno v:
Annals of the Rheumatic Diseases. 81:175-176
BackgroundResults from ORAL Surveillance, a post-authorisation safety study, indicated that patients (pts) with rheumatoid arthritis (RA) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor have an increased risk of major adverse CV e
Autor:
J. T. Giles, C. Charles-Schoeman, M. H. Buch, M. Dougados, Z. Szekanecz, S. R. Ytterberg, G. G. Koch, J. Wu, C. Wang, K. Kwok, S. Menon, Y. Chen, T. Y. Cesur, J. L. Rivas, A. Yndestad, A. Diehl, D. L. Bhatt
Publikováno v:
Annals of the Rheumatic Diseases. 81:518-519
BackgroundORAL Surveillance (NCT02092467) was a post-authorisation safety study of tofacitinib vs tumour necrosis factor inhibitors (TNFi) in patients (pts) with rheumatoid arthritis (RA) aged ≥50 years (yrs) with ≥1 additional cardiovascular (CV
Autor:
M. H. Buch, C. Charles-Schoeman, J. Curtis, M. Dougados, D. L. Bhatt, J. T. Giles, S. R. Ytterberg, G. G. Koch, I. Vranic, J. Wu, C. Wang, K. Kwok, S. Menon, J. L. Rivas, A. Yndestad, C. A. Connell, Z. Szekanecz
Publikováno v:
Annals of the Rheumatic Diseases. 81:356-357
BackgroundORAL Surveillance was a post-authorisation safety study of tofacitinib vs TNF inhibitors (TNFi) in rheumatoid arthritis (RA) patients (pts) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor and an inadequate response to me
Autor:
G. Karpouzas, Z. Szekanecz, E. Baecklund, T. Mikuls, D. L. Bhatt, H. Shi, C. Wang, G. Sawyerr, Y. Chen, S. Menon, C. A. Connell, S. R. Ytterberg, M. Mortezavi
Publikováno v:
Annals of the Rheumatic Diseases. 81:517-518
BackgroundUncontrolled rheumatoid arthritis (RA) activity and acute disease flares are associated with higher risk of adverse outcomes such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy and infection.1-4ObjectivesTo evaluat
Autor:
C. Charles-Schoeman, M. H. Buch, M. Dougados, D. L. Bhatt, J. T. Giles, S. R. Ytterberg, G. G. Koch, I. Vranic, J. Wu, C. Wang, S. Menon, J. L. Rivas, A. Yndestad, C. A. Connell, Z. Szekanecz
Publikováno v:
Annals of the Rheumatic Diseases. 81:611-612
BackgroundORAL Surveillance (NCT02092467) was a post-approval safety study of tofacitinib vs TNF inhibitors (TNFi) in rheumatoid arthritis (RA) patients (pts) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor and an inadequate respo
Autor:
Z. Szekanecz, J. T. Giles, M. H. Buch, S. R. Ytterberg, M. Dougados, D. L. Bhatt, G. G. Koch, I. Vranic, J. Wu, C. Wang, K. Kwok, S. Menon, J. L. Rivas, A. Yndestad, C. A. Connell, C. Charles-Schoeman
Publikováno v:
Annals of the Rheumatic Diseases. 81:278.2-279
BackgroundORAL Surveillance was a post-authorisation safety study of tofacitinib vs tumour necrosis factor inhibitors (TNFi) in patients (pts) with rheumatoid arthritis (RA) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor and an i
Autor:
F W, Miller, W, Chen, T P, O'Hanlon, R G, Cooper, J, Vencovsky, L G, Rider, K, Danko, L R, Wedderburn, I E, Lundberg, L M, Pachman, A M, Reed, S R, Ytterberg, L, Padyukov, A, Selva-O'Callaghan, T R, Radstake, D A, Isenberg, H, Chinoy, W E R, Ollier, P, Scheet, B, Peng, A, Lee, J, Byun, J A, Lamb, P K, Gregersen, C I, Amos, Hemlata, Varsani
Publikováno v:
Genes & Immunity. 16:470-480
Autoimmune muscle diseases (myositis) comprise a group of complex phenotypes influenced by genetic and environmental factors. To identify genetic risk factors in patients of European ancestry, we conducted a genome-wide association study (GWAS) of th
Autor:
M. Gecene, F. Tuncay, P. Borman, D. Yucel, M. Senes, B. KaniyeYilmaz, L. Franks, R. Radusky, J. Feig, P. Fernandez, B. Cronstein, E. Chan, G. Kim, S. Han, Y. Jung, S. E. Usmani, V. Ulici, F. Beier, M. J. Bell, P. Veinot, G. Embuldeniya, J. Nyhof-Young, J. Sale, J. Sargeant, P. Tugwell, S. Brooks, S. Ross, R. Tonon, D. Richards, J. Boyle, K. Knickle, S. Sandhu, N. Britten, E. Bell, F. Webster, M. Cox-Dublanski, E. Ntatsaki, R. A. Watts, D. G. I. Scott, O. Tasbas, H. Gurhan Karabulut, A. Tukun, R. Yorgancioglu, I. Ferraz-Amaro, M. Arce-Franco, V. Hernandez-Hernandez, E. Delgado-Frias, M. Gantes, J. Ramon Muniz, M. Jesus Dominguez-Luis, A. Herrera-Garcia, J. Antonio Garcia-Dopico, L. Medina, A. Rodriguez-Vargas, F. Diaz-Gonzalez, E. Zampeli, A. Protogerou, K. Stamatelopoulos, K. Fragiadaki, C. G. Katsiari, K. Kyrkou, C. M. Papamichael, M. Mavrikakis, P. Nightingale, P. P. Sfikakis, A. Karanasos, I. Felekos, C. Aggeli, C. Stefanadis, K. Toutouzas, S. T. Faezi, M. Akbarian, A. Jamshidi, M. Hoseynialmodarresi, F. Davatchi, B. San Koo, M. Wook So, Y.-G. Kim, C.-K. Lee, B. Yoo, K. J. Warrington, T. A. Kermani, C. S. Crowson, S. R. Ytterberg, G. G. Hunder, S. E. Gabriel, E. L. Matteson
Publikováno v:
Rheumatology. 51:i15-i18
Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Autor:
E M, Miloslavsky, U, Specks, P A, Merkel, P, Seo, R, Spiera, C A, Langford, G S, Hoffman, C G M, Kallenberg, E W, St Clair, N K, Tchao, L, Viviano, L, Ding, D, Iklé, M, Villarreal, B, Jepson, P, Brunetta, N B, Allen, F C, Fervenza, D, Geetha, K, Keogh, E Y, Kissin, P A, Monach, T, Peikert, C, Stegeman, S R, Ytterberg, J H, Stone
Publikováno v:
Arthritis & Rheumatology, 66(11), 3151-3159. Wiley
Objective. Disease relapses are frequent in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). This study was undertaken to evaluate outcomes in patients with AAV who are re-treated with rituximab (RTX) and prednisone for severe diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::657c1a7e5eb4a5ccc4d92b8fe2679651
https://research.rug.nl/en/publications/9f7d5b00-f8c4-4289-b3a5-25cabbae67b3
https://research.rug.nl/en/publications/9f7d5b00-f8c4-4289-b3a5-25cabbae67b3
Autor:
S R, Ytterberg
Publikováno v:
Current Opinion in Rheumatology. 11:275-280
Identifying viral infections related to rheumatic syndromes and understanding the pathophysiologic mechanisms by which they cause disease are crucial steps to furthering our understanding of the pathogenesis of rheumatic disease. Many common viral in